2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Pediatric, Young Adult
PAPER

4880 Distinct subsets of fetal liver LT-HSC exhibit inflammation-induced lineage biases

Alex Murison, PhD, Clinton Piper, MD, PhD2, Murtaza Nagee3, Christy Smolak4, Dominic Didiano5, Liqing Jin6, John E. Dick, PhD7, Eric Lechman, PhD8
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
2 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
4 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
5 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
8 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

A variety of published single-cell multi-omics studies have revealed greater heterogeneity than previously expected at the apex of the hematopoietic hierarchy across ontogeny. However, our understanding of human hematopoietic stem cell (HSC) heterogeneity at this stage is impeded by difficulties in obtaining sufficient numbers of fetal HSCs. To this end, we generated a single cell multi-omic atlas of fetal liver (FL) hematopoietic stem and progenitor cells (HSPC), with ~5x greater resolution of HSC than previous studies, from 7 disomic and 6 Trisomy 21 (Ts21, aka Down Syndrome) sex-balanced donors, capturing both the transcriptome and chromatin accessibility. Leveraging ATAC-Seq signatures of highly purified and functionally validated populations derived from our prior studies revealed three distinct HSC populations which varied in frequency between disomy and Ts21. The transcriptomic differences between these two conditions within HSC populations were more robust than those observed in any other population, and globally these three populations of HSCs were identified within distinct clusters; one similarly abundant in both conditions, one overrepresented in Ts21, and a third overrepresented in disomy. 

This led us to ask whether changes in the relative abundance of HSC populations drive Ts21-associated phenotypes. Gene expression changes within the Ts21-specific HSC population were distinct and particularly enriched for erythroid programs, inflammatory insult and TNFα signalling. Unexpectedly,Ts21-specific HSC were enriched for an aging signature obtained from older bone marrow HSCs. Thus, this population explained many of the phenotypes typically associated with Ts21 such as constitutive inflammatory pressures, premature ageing and erythroid bias during hematopoiesis. Leveraging previously defined signatures for erythroid primed multipotent progenitors (MPP) (Notta et al, 2016) we observed, that TNFα signalling was also correlated with an early erythroid lineage-committed MPP in disomic HSPC, and was lost in downstream erythroid progeny both in disomy and Ts21. However, in Ts21, TNFα signalling was not restricted to the MPP level, but was uniquely enriched at the HSC apex of the hematopoietic hierarchy, further suggesting that these processes may be aberrantly active at the HSC-level in Ts21. We used CD109 as a putative marker based upon gene expression changes, and observed that (when sorted in conjunction with CD49f) we captured a population with strong erythroid bias. Based upon the magnitude of gene expression changes, the EGFR-receptor ligand, Amphiregulin (AREG) emerged as the strongest candidate for mediating the transcriptomic state of this Ts21 HSC subset. Functional studies showed that treatment of disomic FL HSCs with recombinant AREG was sufficient to drive these HSCs into a similarly erythroid-biased state.

In contrast, the population overrepresented in disomy showed stronger enrichment for lymphoid biased gene expression programs. The receptor adhesion molecule Contactin-Associated Protein-Like 2 (CASPR2) was the most differentially expressed gene within this population by several orders of magnitude, and was amenable to use as a flow sorting marker. Isolating cells from this population, we confirmed via limiting dilution assay that it contained bona fide LT-HSCs at a similar proportion to conventionally sorted CD49f+ LT-HSC, and by single cell stromal assays shows an increased bias towards lymphoid output. Surprisingly CASPR2 may also be directly important for mediating this lymphoid bias, since culturing on MS5 stroma expressing its receptor ligand, Contactin2 (CNTN2) further enhanced this bias. 

Our high resolution profiling of the LT-HSC niche in human fetal liver reveals that many of the hematopoietic phenotypes which have been broadly associated with Ts21 may be most profound in a specific sub-population of LT-HSC rather than affecting Ts21 hematopoiesis uniformly. The emergence of this population appears to be at the expense of a lymphoid-biased counterpart, more common in disomic LT-HSC.. Taken together, we suggest that phenotypes central to Ts21 such as premature ageing and increased inflammatory signalling predominate specifically within the HSC niche, and are driven by shifting HSC population dynamics.

Alex Murison, PhD: No relevant conflicts of interest to declare.